Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

p> patients. Preliminary data from this trial will be presented at the

American Society of Clinical Oncology meeting in June.

Genzyme is developing a new filing for the adult AML indication in

Europe. This follows its withdrawal of Bioenvision's marketing

application, which, as expected, an advisory committee deemed

insufficient to support approval. Genzyme expects to make a new

submission as early as the fourth quarter of this year that will

include a more robust data package from Genzyme sponsored studies.

Alemtuzumab for multiple sclerosis

-- Final, three-year efficacy and safety data from the Phase 2 trial

comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment

of relapsing-remitting multiple sclerosis were presented last week

during a scientific platform session at the American Academy of

Neurology meeting by Dr. Alasdair Coles. These results confirm all

trends observed in the one- and two-year interim analyses. The two

ongoing Phase 3 trials further examining the efficacy and safety of

alemtuzumab for the treatment of MS are progressing. These two studies

are currently enrolling patients at sites in the United States, Europe,

Latin America and Australia. Genzyme believes that alemtuzumab has the

potential to be the best therapy in a market for MS drugs that is

projected to reach $8-9 billion annually when the treatment is expected

to be ready for launch in 2011-2012. Alemtuzumab is being developed in

collaboration with Bayer Schering Pharma AG, Germany.

Genz-112638 for Gaucher disease

-- Genzyme is making excellent progress in developing the small molecule

Genz-112638, a novel oral therapy intended for the treatment of Gaucher

disease. Initial results released one year ago for the first group of

stud
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Following the successful launch of On ... to introduce its new product and demonstrate its potential ... Launched in September, Formedix On Demand Services is the ... automation tools. For the first time, these market-leading tools ... introducing Formations – a revolutionary new token-based payment system ...
(Date:10/31/2014)... 31, 2014 The report "Dairy ... Formulation (Plain, Flavored, Sweetened, Unsweetened), Channel (Supermarket, Health ... Trends & Forecast to 2018," defines and segments ... and forecast of revenue and volume for plant-based ... projected to reach $14 Billion by 2018 with ...
(Date:10/31/2014)... 2014 ENVIRON , an ... today that Dr. Harvey Clewell III has rejoined ... work closely with senior professionals in ENVIRON’s Health ... serve at The Hamner Institutes for Health Sciences ... where he is Director, Center for Human Health ...
(Date:10/31/2014)... 31, 2014  Tavistock Development Co. (TDC), a ... celebrated the groundbreaking of the GuideWell Innovation Center ... The 92,000-square-foot, three-story facility is the first ... designed specifically for life sciences, health innovation, ... the 650-acre Lake Nona Medical City, near the ...
Breaking Biology Technology:Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3
... silicon transistors in your computer may be replaced in ten ... scientists at the University of Gothenburg are hoping they ... Silicon is subject to certain limitations, and industry is ... sales of over USD 200 billion, and this means that ...
... Mass. , June 1 Merrimack Pharmaceuticals today announced that it will present ... Mulroy , President and Chief Executive Officer, will provide a company overview at 11:00am EDT ... , New York . , , , ... Merr i mack , ...
... LAKE CITY , June 1 Glycosan BioSystems ... gaining regulatory approval within the European Union for the use ... autologous adipose derived cells in reconstruction and aesthetic plastic surgery ... Mark as an implantable medical device.  HyStem-Rx will ...
Cached Biology Technology:Faster computers with nanotechnology 2Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference 2Glycosan BioSystems Seeks CE Mark in the European Union for HyStem-Rx, a Unique, Implantable Scaffold for Tissue Engineering 2
(Date:10/29/2014)... household and industrial products are in the environment – ... of them, scientists have yet to determine whether they ... toward doing that by estimating which substances people are ... in the ACS journal Environmental Science & Technology ... the risks to human health of any given substance ...
(Date:10/29/2014)... New York City on September 19, 2014, leading geneticist ... Professor of Genome Sciences and Medicine at the University ... Philosophy of Tel Aviv University, was awarded the 2014 ... addition to her honorary degree from TAU, Prof. King ... of Medicine, and for the past 18 years she ...
(Date:10/29/2014)... news release is available in German . ... like another: Gabriela Cabral and Peter Schlögelhofer at the ... Vienna and the Medical University of Vienna dived into ... revealed that these plants display an inversion of the ... in the scientific journal Nature Communications . , ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Meiotic cell division 'the other way round' 2
... new quarterly newsletter for academic librarians and information professionals. ... developments at OUP and across the publishing world. ... and member of the Editorial Team said: ,After careful ... developed a strong and broad source of information for ...
... has been largely overlooked by the public until now. ... of 157 scientists (the Nasonia Genome Working Group) ... University of Rochester, and Stephen Richards at the Genome Sequencing ... the genomes of three parasitoid wasp species. The genomes reveal ...
... 500,000 funding for the Peninsula Dental School to pursue three ... was announced today. The first area of research will ... published evidence and the creation of new approaches to understanding ... will look at the use of virtual reality and psychological ...
Cached Biology News:Genome advances peril for pests 2Genome advances peril for pests 3Genome advances peril for pests 4University of Plymouth invests in dental research 2
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
... the only microplate sealer with an integrated ... times with a variety of configurations and ... with integrated stacker and 240-plate storage capacity ... use in small workcells , Handles all ...
... of mouse embryonic stem cells to dopaminergic ... midbrain, where they are mainly located in ... and the retrorubral field. These dopaminergic (DA) ... innervation ( e.g.projections to the caudate nucleus, ...
... DNA aptamer screening and binding optimization and ... microfluidic on-chip synthesis platform. Thousands of customer ... LC Sciences can provide assistance with custom ... part of our comprehensive DNA/RNA Aptamer Microarray ...
Biology Products: